the psychiatric community would jump for joy for a really good non-stimulant AHDH drug, it would be a very big deal. A very big drug. CX-1739.....who knows but I'll bet if it runs trials in the 3rd quarter there will be anticipation and a much higher stock price. They nailed the "reliable" animal tests, good phase 2a data and it's a $4-5 stock, you catch my drift why this .59 is such a joke?
Your hindsight isn't 20/20. Perhaps an on staff seer could have led them to do a financing before the FDA slapped a hold on C717. I can't even imagine the howling you would have done had they "sucked it up with R&R". There was nothing BS about the "ADHD route" when they launched those trials. NOBODY thought that was a bad idea AT THAT TIME. The financings done have brought us here, still afloat. The only partnerships available in the last three years would have had horrible terms.
I get that you're frustrated. I just don't see management as its cause.
Market Data 
Markets 
AI
